References

(in order of presentation)

The p75 neurotrophin receptor promotes amyloid-beta(1-42)-induced neuritic dystrophy in vitro and in vivo.
Knowles JK, Rajadas J, Nguyen TV, Yang T, LeMieux MC, Vander Griend L, Ishikawa C, Massa SM, Wyss-Coray T, Longo FM.
J Neurosci. 2009 Aug 26;29(34):10627-37.

Modulation of p75-dependent motor neuron death by a small non-peptidyl mimetic of the neurotrophin loop 1 domain.
Pehar M, Cassina P, Vargas MR, Xie Y, Beckman JS, Massa SM, Longo FM, Barbeito L.
Eur J Neurosci. 2006 Sep;24(6):1575-80.

Small molecule, non-peptide p75 ligands inhibit Abeta-induced neurodegeneration and synaptic impairment.
Yang T, Knowles JK, Lu Q, Zhang H, Arancio O, Moore LA, Chang T, Wang Q, Andreasson K, Rajadas J, Fuller GG, Xie Y, Massa SM, Longo FM.
PLoS One. 2008;3(11):e3604. Epub 2008 Nov 3.

ADDF model review

'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease?
Zahs KR, Ashe KH.
Trends Neurosci. 2010 Aug;33(8):381-9. Epub 2010 Jun 9.

Probing the biology of Alzheimer's disease in mice.
Ashe KH, Zahs KR.
Neuron. 2010 Jun 10;66(5):631-45. Review.

Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study.
Mega MS, Dinov ID, Porter V, Chow G, Reback E, Davoodi P, O'Connor SM, Carter MF, Amezcua H, Cummings JL.
Arch Neurol. 2005 May;62(5):721-8.

Detection by voxel-wise statistical analysis of significant changes in regional cerebral glucose uptake in an APP/PS1 transgenic mouse model of Alzheimer's disease.
Dubois A, Hérard AS, Delatour B, Hantraye P, Bonvento G, Dhenain M, Delzescaux T.
Neuroimage. 2010 Jun;51(2):586-98. Epub 2010 Mar 4.

PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET.
Venneti S, Lopresti BJ, Wang G, Hamilton RL, Mathis CA, Klunk WE, Apte UM, Wiley CA.
Neurobiol Aging. 2009 Aug;30(8):1217-26. Epub 2008 Feb 21.

In-vivo measurement of activated microglia in dementia.
Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, Banati RB.
Lancet. 2001 Aug 11;358(9280):461-7. Erratum in: Lancet. 2001 Sep 1;358(9283):766.

A controlled trial of natalizumab for relapsing multiple sclerosis.
Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O'Connor PW; International Natalizumab Multiple Sclerosis Trial Group.
N Engl J Med. 2003 Jan 2;348(1):15-23.

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.
Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jäger HR, Clifford DB.
N Engl J Med. 2006 Mar 2;354(9):924-33.

Anti-JC virus antibodies: implications for PML risk stratification.
Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, Pace A, Cheung A, Chen LL, Berman M, Zein F, Wilson E, Yednock T, Sandrock A, Goelz SE, Subramanyam M.
Ann Neurol. 2010 Sep;68(3):295-303.

Academic Models of Drug Discovery: Services and Utilizing CROs >